Skip NavigationSkip to Content
Return Return to Search Results

Artificial intelligence in COVID-19 drug repurposing

  1. Inventor:
    Zhou, Yadi
    Wang, Fei
    Tang, Jian
    Nussinov,Ruth
    Cheng, Feixiong

  2. Inventor Address

    Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Department of Population Health Sciences, Weill Cornell Medical College, Cornell University, New York, NY, USA., Mila-Quebec Institute for Learning Algorithms and CIFAR AI Research Chair, HEC Montreal, Montr 233;al, QC, Canada., Cancer and Inflammation Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA., Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.,
    1. Year: 2020
    2. Date: DEC
    3. International Patent Classification: 2020 09 18
  2. Published Source: The Lancet. Digital health
    1. 2
    2. 12
    3. Pages: E667-E676
  4. Patent Type: Review
  5. Patent Number: 2589-7500
  1. Abstract:

    Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic. © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/S2589-7500(20)30192-8
  3. PMID: 32984792
  4. PMCID: PMC7500917
  5. View record in Web of Science®
  6. WOS: 000594484100009
  7. PII : S2589-7500(20)30192-8

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel